STEX

Company Overview — What Does BioSig Technologies, Inc. Do?

BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. The company's proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut. BioSig Technologies, Inc. (STEX) is classified as a micro-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Kenneth L. Londoner and employs approximately 50 people. With a market capitalization of $102M, STEX is one of the notable companies in the Healthcare sector.

BioSig Technologies, Inc. (STEX) Stock Rating — Avoid (April 2026)

As of April 2026, BioSig Technologies, Inc. receives a Avoid rating with a composite score of 24.4/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.STEX ranks #3,991 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, BioSig Technologies, Inc. ranks #690 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

STEX Stock Price and 52-Week Range

BioSig Technologies, Inc. (STEX) currently trades at $1.05. The 52-week high for STEX is $14.11, which means the stock is currently trading -92.6% from its annual peak. The 52-week low is $0.40, putting the stock 162.5% above its annual trough. Recent trading volume was 1.8M shares, reflecting moderate market activity.

Is STEX Overvalued or Undervalued? — Valuation Analysis

BioSig Technologies, Inc. (STEX) carries a value factor score of 11/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 0.81x, versus the sector average of 2.75x.

At current multiples, BioSig Technologies, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

BioSig Technologies, Inc. Profitability — ROE, Margins, and Quality Score

BioSig Technologies, Inc. (STEX) earns a quality factor score of 11/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -30.5%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -21.7% versus the sector average of -33.1%.

Revenue growth is running at -100.0% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

STEX Debt, Balance Sheet, and Financial Health

BioSig Technologies, Inc. has a debt-to-equity ratio of 41.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 1.68x, suggesting adequate working capital coverage. Total debt on the balance sheet is $0. Cash and equivalents stand at $11M.

STEX has a beta of 2.44, meaning it is more volatile than the broader market — a $10,000 investment in STEX would be expected to move 143.5% more than the S&P 500 on any given day. The stability factor score for BioSig Technologies, Inc. is 9/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

BioSig Technologies, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, BioSig Technologies, Inc. reported revenue of $0 and earnings per share (EPS) of $-9.65. Net income for the quarter was $-41M. Operating income came in at $-32M.

In FY 2025, BioSig Technologies, Inc. reported revenue of $0 and earnings per share (EPS) of $-9.65. Net income for the quarter was $-463M. Operating income came in at $-71M.

In Q3 2025, BioSig Technologies, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.47. Net income for the quarter was $-16M. Operating income came in at $-6M.

In Q2 2025, BioSig Technologies, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.74. Net income for the quarter was $-20M. Operating income came in at $-20M.

Over the past 8 quarters, BioSig Technologies, Inc. has experienced revenue contraction from $13,000 to $0. Investors analyzing STEX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

STEX Dividend Yield and Income Analysis

BioSig Technologies, Inc. (STEX) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

STEX Momentum and Technical Analysis Profile

BioSig Technologies, Inc. (STEX) has a momentum factor score of 45/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 40/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 35/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

STEX vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, BioSig Technologies, Inc. (STEX) ranks #690 out of 838 stocks based on the Blank Capital composite score. This places STEX in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing STEX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full STEX vs S&P 500 (SPY) comparison to assess how BioSig Technologies, Inc. stacks up against the broader market across all factor dimensions.

STEX Next Earnings Date

No upcoming earnings date has been announced for BioSig Technologies, Inc. (STEX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy STEX? — Investment Thesis Summary

The quantitative profile for BioSig Technologies, Inc. suggests caution. The quality score of 11/100 flags below-average profitability. The value score of 11/100 indicates premium valuation. High volatility (stability score 9/100) increases portfolio risk.

In summary, BioSig Technologies, Inc. (STEX) earns a Avoid rating with a composite score of 24.4/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on STEX stock.

Related Resources for STEX Investors

Explore more research and tools: STEX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare STEX head-to-head with peers: STEX vs AZN, STEX vs SLGL, STEX vs VMD.